Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

Completed · Phase 1

Conditions studied: Leukemia, Lymphocytic, Leukemia, Acute Lymphocytic Leukemia

In brief

A phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. Trial will study safety, pharmacokinetics, and anti tumor activity of the antibody given as a single agent and with vincristine.

Key facts

Study ID

NCT00313079

Run by

Steven E. Coutre

People needed

9

Starts

2006-05-01

Expected to finish

2009-07-01

Last updated by the study team

2012-07-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1.1 Age Patients must be >= 18 years old at the time of study entry.
• 1.2 Diagnosis
• 1.2.1 Histologic Verification Patients must have had histologic verification of B-lineage ALL with bone marrow relapse or refractory disease that is unresponsive to traditional chemotherapy.
• 1.2.2 For patients WITHOUT prior allogeneic BMT:
• Second or subsequent bone marrow relapse
• Primary refractory marrow disease
• M3 marrow (>25% blasts) or >25% leukemic blasts in peripheral blood
• 1.2.3 For patients WITH prior allogeneic BMT:
• First or subsequent bone marrow relapse post-BMT
• M3 marrow or M2 (>5 % and <25% blasts) if cytogenetic or VNTR confirmation
• 1.3 Confirmation of antibody reactivity 3.1.3.1 Patient's leukemic blasts (peripheral blood or marrow) must be documented to bind mAb 216 in vitro (Teng lab) 3.1.3.2 Patient's RBC documented to NOT express fetal "i" antigen and RBC shown to NOT bind mAb 216 in vitro (Teng lab)
• 1.4 Patient Must Not Be Eligible For Therapies of Higher Priority
• 1.5 Performance Level (See Appendix I) Karnofsky >= 50%
• 1.6 Life Expectancy Must be at least 8 weeks.
• 1.7 Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
• Myelosuppressive chemotherapy: Must not have received within one week of entry onto this study.
• Biologic, including monoclonal antibodies: At least 2 weeks since the completion of therapy with a biologic agent including monoclonal antibodies.
• Hydroxyurea can be used up to 72 hours before study entry
• 1.8 Organ Function Requirements
• 1.8.1 Bone Marrow Function: 3.1.8.1.1 No hematologic criteria for WBC, Hgb or platelets 3.1.8.1.2 Patients with thrombocytopenia should be responsive to platelet transfusions and must not have uncontrolled bleeding.
• 1.8.2 Adequate Renal Function Defined As:
• A serum creatinine that is less than or equal to 2 x normal for age
• 1.8.3 Adequate Liver Function Defined As:
• Total bilirubin <= 2 x upper limit of normal (ULN) for age, and
• SGPT (ALT) <= 5 x upper limit of normal (ULN) for age

You may not qualify if…

• 2.1 CNS 3 or refractory CNS leukemia
• 2.2 Isolated extramedullary relapse
• 2.3 Uncontrolled infection
• 2.4 Lack of mAb 216 binding to patient's leukemic blasts in vitro
• 2.5 Binding of mAb 216 to the "i" antigen on patient's erythrocytes

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.